Seelos Therapeutics is developing psychedelic compounds to deal with needs in CNS disorders and rare diseases. The company buys IP for which they do (pre-)clinical R&D to bring those compounds closer to market.
Seelos Therapeutics
Intense Suicidal Ideation and Behavior in Major Depressive Disorder or Post-Traumatic Stress Disorder, amyotrophic lateral sclerosis (ALS), Sanfilippo syndrome, Parkinson’s disease, psychiatric disorders, and movement disorders, and orphan diseases are among the company’s late-stage clinical assets.
Seelos Therapeutics has raised a total of $51.3M in funding over 2 rounds. Their latest funding was raised on Nov 24, 2021 from a Post-IPO Debt round.
Seelos is listed on the Nasdaq under the ticker SEEL.
Activities
B2B
B2C
Pharmaceutical
Biotech
Explore more company info with a Tree membership
📰 Weekly newsletter about the business of psychedelics
📈 Extended company information (analyst view, fundraising, revenue numbers)
🪄 Priority company page updates